Table of Contents
Table of Contents
Preface
Section I
Chapter 1. Definition, Epidemiology, Natural History and Clinical Phases
(Vamsi Kota and Kavita Natarajan, Georgia Regents University, Augusta, GA, USA)
Section II
Chapter 2. CML: Clinical Diagnosis, Differential Diagnosis and Scoring Systems
(Nelli Bejanyan, University of Minnesota, Minneapolis, MN, USA)
Chapter 3. Chronic Myelogenous Leukemia, Morphology and Immunophenotype
(Melissa Hart and Michael Linden, Division of Hematopathology, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA)
Chapter 4. Cytogenetic and Molecular Aspects of CML
(Michelle Dolan, Michael Spears, and Sophia Yohe, Division of Hematopathology, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA)
Chapter 5. Molecular Mechanisms in CML Pathogenesis
(Vamsi Kota and Jerald P. Radich, Georgia Regents University, Augusta, GA, USA and others)
Chapter 6. Secondary Resistance to Tyrosine Kinase Inhibitors: Focus on Molecular Mechanisms other than BCR-ABL Overexpression and Mutations
(Tereza Lopotová and Markéta Žáèková, Institute of Hematology and Blood Transfusion, Dept. of Cellular Biochemistry, U Nemocnice 1, Prague, Czech Republic)
Section III
Chapter 7. Frontline Therapy
(Pavan Kumar Bhamidipati and Elias Jabbour, Department of Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX, USA)
Chapter 8. Management of Tyrosine Kinase Inhibitors Resistance
(Pavan Kumar Bhamidipati and Elias Jabbour, Department of Leukemia, U.T. M.D. Anderson Cancer Center, Houston, TX, USA)
Chapter 9. Management of Chronic Myeloid Leukemia (CML): Accelerated Phase (AP)
(Mohamad Cherry and Aref Al-Kali, Oklahoma University Health Science Center, Oklahoma City, OK, USA and others)
Chapter 10. Management of Chronic Myeloid Leukemia (CML): Blast Phase (BP)
(Aref Al-Kali, Pavan Kumar Bhamidipati and Elias Jabbour, Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA and others)
Chapter 11. Hematopoietic Cell Transplant for CML
(Fiona He and Erica Warlick, Department of Medicine, and Division of Hematology, Oncology, and Transplant, Department of Medicine,
University of Minnesota, USA)
Chapter 12. Summary of Treatment and Recommended Follow-Up of CML Patients
(Celalettin Ustun, Erica Warlick, Prithviraj Bose, Jerald P. Radich and John Goldman, Division of Hematology, Oncology, and Transplant, Department of Medicine, University of Minnesota, USA and others)
Section IV
Chapter 13. CML in Pediatric Population
(Michael Burke and Lamis Eldjerou, Medical College of Wisconsin, MACC Fund Research Center, Division of Pediatric Hematology-Oncology-BMT, Milwaukee, WI, USA and others)
Chapter 14. Blastic Transformation in Extramedullary Sites
(Isabel Cunningham, Division of Hematology Oncology, Columbia University College of Physicians and Surgeons, New York, NY, USA)
Chapter 15. Managing CML in Pregnancy
(Renuka Palanicawandar, Jane Apperley and Deepti Radia, Centre for Haematology, Imperial College London, London, UK and others)
Chapter 16. Drug and Food Interactions with TKIs
(David DeRemer, University of Georgia College of Pharmacy, Georgia Regents University Cancer Center, GA, USA)
Chapter 17. Molecular Monitoring of CML: Role for Novel Markers Additional to BCR-ABL
(Tereza Lopotová and Markéta Žáèková, Institute of Hematology and Blood Transfusion, Department of Cellular Biochemistry, Prague, Czech Republic)
Section V
Chapter 18. Can We Cure CML without Transplantation?
(Prithviraj Bose and Pankit Vachhani, Massey Cancer Center and the Department of Internal Medicine, Virginia Commonwealth University, VA, USA)
Free Download Available
Commentary
Chapter 19. Future Directions
(Celalettin Ustun and John Goldman, Division of Hematology, Oncology, and Transplant, Department of Medicine, University of Minnesota, MN, USA and others)
Index
Audience: We are humbled to introduce the excellent contributions to, Chronic Myeloid Leukemia: From Daily Management to Complicated Issues, written by esteemed experts in chronic myeloid leukemia (CML). As practicing hematologists and academicians, we believe that this book will serve a diverse audience of medical students, community oncologists, and academic hematologists and their patients.
